TECH OFFERS

Amidst the imposition of compulsory climate reporting by regulatory bodies in some nations including Singapore, a powerful carbon accounting software solution has been devised. This aims to aid and fortify companies in their readiness to adhere to this necessity and embark on their sustainability journey. The software suite consists of the following solutions: GHG Emissions Management: Efficiently manage and reduce your organisation's greenhouse gas (GHG) emissions. ESG Reporting: Streamline and simplify your Environmental, Social, and Governance (ESG) reporting process. Environmental Compliance: Propel your organisation towards comprehensive ISO 14001 environmental stewardship. 24/7 Electricity Emissions Traceability: Navigate your decarbonisation journey with real-time, precise and transparent electricity emissions tracking. GHG Emissions Management At the heart of the software suite is the GHG Emissions Management solution. An all-in-one GHG emissions management software, to streamline calculating, tracking, and reporting your organisation's greenhouse gas (GHG) emissions for Scope 1, 2, and 3 activities. Accurate & Instant Emissions Calculations Transparent Target Setting & Progress Tracking Actionable Insights for Emissions Reduction Seamless Integration & Automation Data Validation & Stakeholder Engagement Offset Your Unavoidable Emissions Simplified Reporting & Compliance ESG Reporting Navigating the complex world of ESG reporting is now easier than ever with a powerful, user-friendly solution designed to save your organisation time, reduce stress, and optimise your reporting process across multiple international frameworks. Easily share disclosure questions to individuals across your company, manage their response and get knowledge from your disclosures by turning them from a compliance burden to valuable business insight. ESG Framework Templates Hub – GRI, TCFD, CDP, SASB and more ESG Data Consolidation Portal   Customised Data Insights Suite Environmental Compliance The solution incorporates features to support you when complying with ISO14001. Store all documents in one place, identify nonconformities, and create effective action plans. Audit Management and Reporting Data Health Check and Warnings Documentation Repository Data Verification and Tracking Automated Data Collection Target Setting and Tracking Electricity Emissions Traceability Our latest feature is Electricity Emissions Traceability: Get real-time, precise and transparent electricity emissions tracking telling you the intensity of the electricity from your grid on an hourly basis.   The suite of solutions are aimed at organisations taking proactive steps to measure and report their environmental and social impacts. GHG Emissions Management: Aimed at those organisations already calculating their carbon footprint looking for a more efficient solution or consultants providing carbon accounting as a service. ESG Reporting: Is useful for organisations already struggling with the compliance burden of disclosing to a different frameworks looking for ways to increase the efficiency of the process. Environmental Compliance: A solution perfect for any organisation who is ISO14001 accredited. 24/7 Electricity Emissions Traceability: A must have for those trailblazers wanting to go that step further and set an example for more accurate scope 2 reporting to encourage carbon free energy production locally.  This software solution provides sustainability consultants and partners allowing for a well-structured solution implemented quickly for their clients. This suite of software solutions is unique in combining a powerful carbon accounting tool with ESG reporting framework support, ISO14001 compliance functionality and real time scope 2 emissions reporting. Limited software company provides this suite of solutions designed to help you collect, calculate, measure, report and disclose your ESG data.     Infocomm, Big Data, Data Analytics, Data Mining & Data Visualisation, Green ICT, Sustainability, Low Carbon Economy

In 2022, about 83 million patients suffer from insulin-dependent diabetes worldwide. From 2021 to 2045, this number is projected to increase by 46% globally. Despite the availability of approved insulin therapy as the standard of care, up to a quarter of these patients still suffer from poor blood glucose control, which can lead to a fatal drop in blood glucose levels. The team has developed a cell-encapsulating macro-device as an implant to reduce the risk of fatal drop in blood sugar of insulin-dependent diabetic patients. This patent-pending, injection-free cellular implant can effectively manage insulin-dependent diabetes by enabling enhanced survival of therapeutic insulin-secreting cells. After a simple under-skin insertion of the macro-device, the cells in this implant can sense the blood glucose level of a diabetic patient and secrete insulin to continuously provide injection-free, precise glucose control. The device also protects the insulin secreting therapeutic cells by encapsulating them in a hydrogel to shield them from immune attacks and alleviate the patient from the need for immunosuppression. This technology could offer a safer alternative treatment for these insulin-dependent patients who experience poor blood glucose control with conventional insulin therapy. This platform technology includes two main components: a protective hydrogel membrane and living therapeutic cells. These cells are encapsulated within the hydrogel, which has controllable pores. These pores are large enough for nutrients and therapeutic agents to pass through, allowing the cells to survive and function normally. Furthermore, the pore size is small enough to block the entry of immune cells and harmful molecules, protecting the therapeutic cells from the patient's immune system. This protection eliminates the need for lifelong use of immunosuppressants, easing the burden on the patient. Once implanted inside the patient, the therapeutic cells inside the device can sense the biological environment and secrete their therapeutic agents, typically insulin in the case of diabetes, as required. The proprietary device design also improves oxygen access for the therapeutic cells by arranging them in donut-shaped microtissues, providing more surface area for oxygen intake compared to their natural spheroidal shape. These microtissues are then organized into arrays to prevent aggregation, enhancing survival of the therapeutic cells and potentially prolonging treatment duration without the need for additional agents or accessories. The technology development is currently focusing on treatment for insulin-dependent diabetes. In addition to this indication, it could serve as a platform technology for the treatment of other hormone-deficiency diseases by encapsulating different types of therapeutic cells to secrete missing hormones of interest. The applicable indications include, but are not limited to, hemophilia A and thyroid disorder. With 83 million patients worldwide suffering from insulin-dependent diabetes in 2022, there is an urgent unmet need for a safer alternative treatment for patients unresponsive to insulin therapy. The proposed cellular therapy has the potential to fulfil this need, and there is no similar treatment already approved and available in the market. Targeting the young insulin-dependent patient population (Type 1 Diabetes) experiencing poor blood glucose control and able to afford the treatment, it is estimated that the service obtainable market in the United States could achieve an annual revenue of approximately 70 million USD. A similar estimation values the Chinese market at 37 million USD annually.  The  macro-device implant is designed to provide continuous and precise blood glucose control without requiring manual intervention and injection. The proprietary hydrogel design provides protection from immune rejection as alleviating the patient from the burden of lifelong immunosuppressant usage. The device design also potentially improves the survival of encapsulated cells, promising a sustainable and prolonged efficacious duration without overburdening the patient with additional accessories. diabetes, type 1 diabetes, injection free insulin delivery, insulin, insulin delivery, cell therapy, therapeutics, stem cells, hydrogel, implant, implant device Healthcare, Medical Devices, Pharmaceuticals & Therapeutics

Histopathology is a cornerstone of modern medicine, providing crucial information that enables doctors to formulate optimal treatment strategies before, during, and after surgeries. However, current methods for obtaining histological images grapple with a compromise between speed and accuracy and suffer from organ-dependent inconsistencies. Addressing these challenges, our technology was developed as a versatile solution to cater to a wide array of clinical scenarios. It sets a new benchmark for medical standards with its rapid, precise, and label-free on-the-spot imaging capability. Computation High-throughput Autofluorescence Microscopy by Pattern Illumination is a one-of-a-kind patented solution n that can detect and provide instant information about cancer status before, during, and after surgeries. This technology lets surgeons place fresh tissue samples taken directly from the patient into the microscope and receive high-resolution and virtually stained histological images in just three minutes. The primary adopters of this technology are expected to be healthcare organizations, hospitals, and research institutions, or any entity involved in histopathology, cancer diagnosis, and surgery. This technology fills a crucial void in the market by providing swift, high-resolution, label-free imaging of thick tissue samples, an achievement previously unattainable. Consequently, this technology not only accelerates the diagnostic process but also enhances its precision, revolutionizing the field of histopathology This is an innovative solution designed to revolutionize histological imaging. It consists of several key components that contribute to its functionality: Ultraviolet Light Source: The microscope uses UV light to excite the surface of the specimen, which generates autofluorescence from the biomolecules. This autofluorescence is then captured to produce a high-resolution grayscale image. Low-magnification Objective Lens: This component provides a large field of view and is insensitive to the surface roughness of the sample. Despite its low magnification, it contributes to the high imaging speed of the technology. Pattern Illumination: This technique has been incorporated to overcome the limitations of the low-magnification lens. It helps to mathematically retrieve high-frequency signals and reconstruct high-resolution images by capturing more details and contours. Deep-learning Algorithm: This deep learning algorithm is developed to virtually stain the grayscale images with over 90% accuracy, transforming them into virtually stained H&E images. This aids in the interpretation of the images by pathologists, facilitating an easier and swift adaptation of the technology. The technology holds immense potential across various sectors, predominantly in healthcare and medical research. It can be utilized during biopsy sessions preceding surgeries, providing doctors with a rapid means to verify sample sufficiency. This capability can minimize the need for repeated biopsies, thereby improving patient comfort and experience. Furthermore, it aids in preserving the integrity of the tissue sample, facilitating subsequent consumptive testing. In the operating room, this technology can serve as an intraoperative imaging tool, potentially replacing frozen sections. This enables more rapid and precise intraoperative margin analysis during various cancer resection surgeries. With its capacity for swift and accurate imaging of freshly-excised thick tissue, our technology  is anticipated to play an instrumental role in promoting conservative surgeries. Such procedures aim to preserve more normal tissues during tumor removal, enhancing patient physiological function and life expectancy without compromising treatment efficacy. Lastly, the device can function as a tool for the digitization of tissue samples post-surgery. Hospitals often retain tissue samples for up to 10 years as a reference record. However, physical storage demands significant space and resources to maintain tissue conditions. The  ability to digitize these tissues provides a more accessible and convenient resource for research institutes and doctors to conduct further studies, thereby optimizing storage and potentially expediting medical research. The market size for the technology is substantial, considering it serves the healthcare and medical research sectors, both of which are substantial and growing markets. The global histopathology services market was valued at around USD 22.68 billion in 2020 and projected to grow at a CAGR of 6.5% from 2021 to 2028, reaching approximately USD 37 billion by 2028. The market for medical imaging equipment, which the CHAMP Microscope™ would also fall under, was projected to reach USD 43.3 billion by 2027. These figures suggest a substantial potential market for the technology. This technology stands as a significant improvement over the current clinical gold standard in histopathological imaging. The traditional methods, including Formalin-fixed Paraffin-Embedded (FFPE) and frozen section analysis, are either time-consuming or lack precision.  The Unique Value Proposition (UVP) lies in the ability to significantly reduce the time required for histopathological imaging while maintaining high accuracy this technology   Speed and Accuracy:  Offer a high-resolution, label-free imaging solution that can generate high-quality images in just three minutes, a significant improvement over current histopathology methods. Thick Tissue Staining : Technology can be used with both slides and freshly-excised thick tissue, eliminating the need for labour-intensive tissue processing and chemical staining. Versatility: The technology is applicable across a wide range of clinical scenarios, making it a versatile tool for various healthcare and research institutions. Deep Learning Model : The integration of a deep learning algorithm  for virtual staining enhances the technology's appeal by minimizing the learning curve for pathologists, making the transition to this new technology smoother. Cost and Resource Efficiency: By enabling on-the-spot imaging and reducing the need for repeated biopsies and surgeries, the technology can lead to significant cost and resource savings for healthcare providers. Patient Outcomes: By facilitating real-time decision-making during surgeries, the technology can improve patient outcomes. In sum, the technology offers a faster, more accurate, and more versatile solution for histopathological imaging, significantly enhancing clinical workflow efficiency and potentially leading to better patient outcomes. This combination of speed, accuracy, and convenience sets apart from the current clinical gold standards. Healthcare, Diagnostics, Medical Devices, Telehealth, Medical Software & Imaging

Patients who have stroke, brain injuries, cerebral palsy, arthritis or suffer from other neurological disorders often experience motor impairments; patients with delayed or lack of rehabilitation suffer from more severe physical sequelae, such as, spasticity and muscle atrophy, which decreases their level of independence It has been reported by World Health Organisation, that the need for rehabilitation continues to grow worldwide, especially in low- and middle income countries. The demand for rehabilitation services already exceeds availability, leaving a large unmet need. Longer life expectancies and increasing survival rates for those with severe disability, coupled with the rising prevalence of chronic diseases means that globally there will be an increase in the health burden associated with limitations in functioning. For both the patients and therapists, there is a need for efficient models of rehabilitation care are needed. This invention is of a robotic manipulator that can assist or be programmed to move or mobilize patients’ limbs or joints repetitively during rehabilitation or to perform daily tasks, for e.g., of gripping a cup, bowl or utensil, in a safe, reliable and effective manner. The device can be used in a clinical and/or at-home setting. This invention is of a hybrid robotic manipulator that consists of both soft and rigid materials, with a portable base, modular design and sensing elements integrated for more functions. The technology was developed to aid physiotherapists in doing repetitive rehabilitation motions for bed-ridden patients. This innovative solution for patients allows them to regain their upper limb motor functions and improve their quality of life. The technology can be used as an upper limb rehabilitation system that is portable, comfortable, lightweight, and user-friendly. With its versatility and flexibility, this system can be deployed in places where assistance for rehabilitation of the patients is needed, such as hospitals, rehabilitation centres and elder-care centres to do simple repetitive rehabilitation motions for the patients, such as shoulder flexion/extension, shoulder abduction/adduction, elbow flexion/extension, etc.  The global rehabilitation robots market was valued at USD 226.0 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 17.3% from 2022 to 2030 (Source: Grand View Research). The growth can be attributed to the rising per capita healthcare spending and rapid adoption of technologically advanced equipment in the healthcare sector. The rising prevalence of stroke and the rapidly growing population of older adults are some of the key driving factors responsible for the growth. Technological advancements are also playing a major role in supporting industry growth. Furthermore, increasing disorders such as cumulative trauma disorder, repetitive strain injury, and occupational overuse syndromes further impact the market positively. A large population with musculoskeletal disorders, spinal cord injury, and others tend to move to hospitals for rehabilitation services, thereby boosting the growth of the segment. In addition, surging awareness regarding technologically advanced systems, along with a rise in the number of FDA approvals on medical exoskeletons, is anticipated to drive the segmental growth. Couple this, with the acute shortage of qualified physiotherapists to address the expected increase in patient demand, indicates a strong market potential for assistive rehabilitation robotic technologies such as this invention. This hybrid robotic arm ensures better safety during human-robotic interactions, and demonstrated higher force, versatility and portability compared to existing robotic arms. The key feature of this invention provides: Better safety: The robotic arm was created with both rigid and soft materials. The core of the hybrid robotic arm was made of aluminium as the supporting structure, and the outer layer was made of fabric air pockets as the protective material. Compared to traditional rigid robotic arms, the hybrid robotic arm ensures better safety during human-robotic interactions, as well as higher portability which increases user convenience. Reconfigurable modular robotic arm: All modules of the hybrid robotic arm are exchangeable, which allows the robotic arm to exhibit different arm length and various configurations such as beam-joint-beam and beam-beam-joint, according to the application requirements. Integrated sensing elements for easier control: Machine Learning based sensing elements are integrated to the system to allow a playback learning capability in which the physiotherapists can teach the system to perform a rehabilitation motion along a desired path of motion, and to provide data for the physiotherapists to track and analyze rehabilitation progress of the patients Physiotheraphy, Soft Robotics, Robotics, stroke rehabilitation, rehabilitation, robots, rehabilitation robots, modular, robotic arm, robotic manipulator Healthcare, Medical Devices

Immune cell activation and expansion for cell therapy is a strictly regulated process. It demands costly and labour-intensive optimization of cell culture conditions. Major limitations of these processes are cell quality and results consistency. Large amounts of expenses were spent on culture conditions, cell characterizations and quality control (QC) with differing culture protocols and recipes in growing CAR-T cells. This technology has established a standardized platform through its feeder-cell mimicking feature that could screen culture conditions for diverse cell types and patient source more rapidly at lower costs. Both feeder-cell based system and feeder-free system poses respective challenges of contamination or insufficient growth signals. To address this gap, a modular, all-signals-in-one microbead-based platform has been developed for the next-generation cell therapy R&D and translation. In this delivery platform design, the modular feature allows rapid ‘plug-and-use’ of multiple surface and soluble signals to grow T-cells ex vivo without the need for extensive setup and integration of culture protocols. This platform aims to provide a seamless and straightforward cell culture experience for the industrial and academic research users to discover new types and applications of immune cell therapy. Additionally, the all-signals-in-one synthetic platform mimics the natural antigen presenting cells to activate and expand T-cells on dish, allowing cell manufacturers to ‘mix-and-grow’ immune cells with reduced effort or technical expertise. This aims to improve the cost-effectiveness and scalability of cell therapy manufacturing. The technology provider is seeking collaborations with cell therapy CDMOs/CMOs in licensing and various R&D developments. The proprietary microbead has 4 modules: the core, shell, surface and soluble signals which are assembled into an artificial cell. The core is a hydrogel microparticle made of chemically modified polysaccharides, produced via membrane extrusion method or high-throughput microfluidics assisted technology to control the particle sizing (from submicron to microns) and uniformity. The shell consists of fluidic lipid membrane surrounding the hydrogel microparticle via proprietary coating technology. The lipid shell can be made of purely synthetic lipid components, such as POPC, biotin-PE, natural lipid extracts from cellular membrane or exosomes, or hybrid to fine-tune the stability, fluidity and bio-functionality. The surface signals are docked on the shell via biotin-avidin interactions. These signals may include but are not limited to, anti-CD3, anti-CD28, anti-CD2, anti-CD137 for CAR-T cell production or different surface signal combinations for other immune cell types. The soluble signals can be loaded into the hydrogel microparticle, such as cytokine, growth factors or other chemical modulators. The release profile can be adjusted with the hydrogel degradation kinetics. From a scale up production point of view, each module could be mass produced and stored independently and assembled into the final microbead product for ex vivo cell activation and expansion. The resulting all-synthetic microbead products are shown to be biocompatible and biodegradable ex vivo and in vivo. Therefore, they have the potential to be used in in vivo T-cell activation and expansion. The proprietary microbead-based platform functions as an artificial cell, with its fluidic membrane surface signals presentation and controlled-released soluble signals. The platform application includes but not limited to: Cell therapy manufacturing: Microbeads can be used to support and supplement ex vivo T-cells activation and expansion. Cell-based therapies and regenerative medicine: Microbeads can be engineered to mimic the functions of specific cell types, such as T-cells for immunotherapy, pancreatic cells for diabetes and glial cells for neuron repair. Versatile high-throughput screening platform bridging in-silica signals discovery and in-vitro validation: The ‘plug-and-use’ microbead-based platform feature, together with the versatility avidin-biotin technology and accessibility of commercial biotinylated recombinant proteins and antibodies enable rapid in vitro tests of novel biochemical signals and combinations on cell functions.   Cell therapy is the next pillar of medicine for the treatment of chronic diseases, such as cancer, autoimmune disorders etc.  The cell expansion market was valued at 41.3B USD in 2021 with a CAGR of 12.6%. Nonetheless, many cell therapeutics are still in the discovery and pre-clinical phase. The clinical translation is hampered by suboptimal culture process, unstandardized protocol, limitations of research tools and ex vivo signals delivery platform and high demand of technical expertise. The predominant player in cell expansion and activation market is the magnetic microbeads with emerging alternatives such as antibody tetramers, polymeric nanomatrix, nanosystems with varying shapes/size/stiffness to expand the cell growth tools, facilitate R&D and translational research of cell therapy. The microbead platform technology mimics cell structures, allows rapid customization of surface and soluble biochemical signals, and enable automation manufacturing process to transform donor cells into therapeutics. The platform is designed to fit existing cell manufacturing automation modalities in the following ways: Microbeads in suspension form for use in bioreactors. All-signals-in-one microbead system to mimic feeder cells to facilitate cell activation and expansion. By-passing of de-bead step to allow adjustable degradation kinetics of microbeads such as active degradation (allow users to degrade beads anytime) or passive degradation (hydrolysis within the hydrogel microparticles). Degraded hydrogel products are polysaccharides, protein, and lipids, which can be removed via standard cell washing process. Furthermore, this technology has shown to increase both CAR-T cell persistence and total number of T-cell production. This platform will accelerate the speed for validating novel soluble and surface signals identified and elucidated through AI and single-cell sequencing technologies/data from tumour microenvironments, patient immune cells profile etc. All in all, this platform brings two unique experiences to the research and industrial users, that are ‘plug-and-use’ and ‘mix-and-grow’ to streamline the cell therapy R&D, translation and scaleup production workflow with greater cost-effectiveness without compromising high quality and reliable cell therapy to millions of patients in need. Cell and Gene Therapy, Cell Manufacturing, Bioreactors, Magnetic Microbeads, Hydrogel, Artificial Cells, Biomaterials, Drug Delivery Platform Healthcare, Pharmaceuticals & Therapeutics, Life Sciences, Industrial Biotech Methods & Processes, Biotech Research Reagents & Tools

This technology portfolio covers wearable sensing and haptics for Virtual Reality (VR). The wearable sensors can provide gesture-based control in VR without the need for cameras, providing interactive control for VR for lower end headset. The sensor use electronic textiles and a patented sensing scheme that requires no additional electronics except a microcontroller. They present ultralow latency (<1ms), can distinguish between wearer and non-wearer and have exceptional noise rejection. The haptics technology allows for simulation of resistance and micro sensations on the fingers and palm. This is crucial for applications like surgical training, as surgeons routinely rely on their sense of touch in real world scenarios. The jamming technology uses textile-based actuators and pneumatics, making it the lightest wearable technology for haptics. Sensing: Textile-based wearable sensors woven into gloves. Custom microcontroller mounted on the glove. Proprietary signal conditioning and processing algorithm. Haptics: 3D-printec micro haptics actuators, as well as 3D printed+ fabric-based jamming actuators.Pnuematics pressure source, valves and control box. VR-based training is the main target for the haptics. The tech owner has signed LOIs with studios with downstream medical clients. The patented sensing methods allows for ultralow latency (<1ms) sensing with almost no hysteresis, which is unique in case of wearable soft sensors. This makes them ideal for use in applications like gaming and other wearable input devices, where other soft sensor leave a lot to be desired for a good user experience.   Sensing: Gaming and VR interaction- without the need for extra cameras: the wearable sensing provides a cheaper alternative to additional headset cameras. Haptics: Medical training professionals- haptics is crucial for applications like surgical training where dexterity needs to be trained. Current applications of VR can only train procedures. XR based training is becoming popular as it saves up to 80% cost compared to traditional methods and improves retention by up to 4x. The market for XR hardware is already a S$2.6B market and growing rapidly. The market is project to grow 40-50% YOY over the next 5 years. This is greatly being aided by addition of application layers such as OpenXR that allow for cross-compatibility between hardware such as the devices we are building. The sensor can distinguish between wearer and non-wearer, has exceptional noise resistance, and the system has extremely low power consumption owing to the sensing method used. The jamming haptics technology uses fabric-based jamming which is the lightest in-class for wearables. This makes it ideal for applications where dexterity is requited- such as VR surgical training. The micro-haptics uses 3D printed designs that supply higher force output at lower pressures due to their patented multi-layer design. Infocomm, Internet of Things

Systemic drug administration has conventionally been prescribed to alleviate persistent local inflammation which is prevalent in chronic diseases. However, this approach is associated with drug-induced toxicity, particularly when the dosage exceeds what is necessitated from the pathological conditions of the diseased tissues. This technology developed is a novel drug delivery technology that is activated to enable the release of appropriate drug payload according to the patient’s condition on the level of disease severity. The drug delivery system is a modular hybrid hydrogel carrier encapsulating the required anti-inflammatory drug which is triggered to release upon exposure to elevated markers of inflammation such as increased protease activity which is commonly upregulated in inflammatory diseases.   The technology has been validated for its material, safety, and toxicity studies on ex vivo exudates of clinical samples, in vivo wound model, and arthritis diseased mouse model. The primary targeted indication is Rheumatoid arthritis based on its significant disease unmet need and market size. It aims to become a platform technology as an effective therapy against chronic inflammatory diseases such as inflammation bowel diseases, chronic wounds and topical application. The convenience of the technology offers significant societal benefits, particularly for ageing populations where the incidence of pain and inflammation arising from diseases becomes prevalent with age while potentially eliminating adverse side effects from traditional delivery of drug administration.  The technology owner is seeking for collaborations with clinicians, biopharma, biotech companies looking for novel drug delivery systems. The platform technology is based on a hydrogel system with a proprietary modular design for which drug component and inflammation-sensing component can be selected and tailored based on the profile of an inflammatory disease of interest. Key features of this platform drug delivery technology are: Modular in design Immuno-compatible Versatile for both injectable into joints and topical application on wound This drug delivery system is formulated into an injectable pain-relieving gel for arthritic patients. With a single injection into the joints of arthritis patients, the therapeutic drug within the hydrogel formulation will be released at a dosage matching the intensity and frequency of inflammation flares to achieve prolonged control of inflammation and pain. This analgesic product solution can help arthritic patients avoid frequent steroid injections while maintaining pain-free joints with minimal risk of adverse side effects. The stage of the technolgy can be applied with Steroidal and Non-steroidal anti-inflammatory drugs (NSAIDs) currently. This drug delivery platform offers a versatile platform for biomarker dependant drug dose release and delivery at appropriate inflammation site via either an injectable or topical application to effectively manage long-term inflammation seen in chronic conditions. The technology can be applied to create precision therapeutics in injectable or topical formulation to treat chronic inflammation conditions such as arthritis, skin inflammatory diseases, Inflammatory Bowel Diseases (IBD), chronic wounds and Chronic Obstructive Pulmonary Diseases (COPD) which can be potentially expanded to other areas including eye, skin and dental as a pain control for inflammation and the possibility of encapsulating proteins and peptides. The estimated Total Available Market (TAM), which is the global rheumatology therapeutics market, was USD 48.4 billion in 2020 with an expected growth to USD $64.4B by 2028, expanding at a CAGR of 3.1% during this forecast period. The Serviceable Available Market (SAM), estimated base on corticosteroid market for management of arthritic flare as the primary indication, accounts for 25% of joint-pain injection market which will be worth USD $9.2 billion by 2030. The technology is in PCT national regional phase entry for several markets including USA, China, EU, Japan, Korea, and Australia.  Key features of this precision medicine: Effective management of inflammatory condition Minimize adverse side effects Minimize frequency of drug administration Precision Medicine, Drug Delivery, Anti-inflammation, Chronic disease, Hydrogel, Arthritis Healthcare, Medical Devices, Pharmaceuticals & Therapeutics

Singapore has a high consumption of fruits and vegetables, both locally produced and imported, and a significant portion of the total waste generated is derived from fruits and vegetables. These fruits and vegetables contain untapped nutritional and functional properties that can be upcycled into higher value products. This institute of higher learning has developed a technology with the know-how to cultivate microorganisms and a series of zero-waste extraction and purification methods to maximize the value of fruit peels into functional food ingredients.  This technology is designed for three types of industry players: i) fruit vending/processing industry with abundance of good quality fruit by-products; ii) waste management industry with technologies to value add to the by-products; and iii) start-ups with keen interest to upcycle by-products into novel food ingredients. The technology is a sustainable process and here are some key features: Zero waste solution – achieving circular economy Low-carbon economy, reduced waste during manufacturing Easy to assemble using off-the-shelf commercial-ready equipment Low CAPEX, modular installation Simple method – any technician with basic training and carry out the process Scalable – abundance of fruit by-products to achieve economies of scale A reactor for pilot scale testing at a reasonable cost has been fabricated for collaborators to tap on. Food-grade microbial protein: A protein-rich source of food ingredient with functional properties to be applied into beverages, confectionery, plant-based meats Pectin from fruit peels: A finished product upon extraction process, it is rich in soluble dietary fiber that can be used as natural thickener or in jam/sauces and beverages. Cleaning agents: Antimicrobial properties were observed in the fruit peels post extraction Good quality fruit by-products from fruit industry are valuable resources for upcycling. These materials are currently disposed  by incineration. With the high moisture content of fruit peels, incineration is energy-intensive leading to higher CO2 emission. This technology produces valuable food ingredients such as protein and dietary fiber, contributing to both food security and circular economy. microbial protein, dietary fiber, dietary fibre, fuit by-product, fruit peel, zero waste, sustainable food ingredients, fruit waste, food waste, upcycle, food valorisation Waste Management & Recycling, Food & Agriculture Waste Management, Sustainability, Circular Economy, Food Security

Population aging is a global phenomenon as most industrialized countries are experiencing growth in the size and proportion of elderly citizens in their population. The percentage of older adults is estimated to be double by 2050 than that in 2019, which will place new challenges on the social economy and healthcare. The increasing population of elderly people requires great attention to be paid to age-related problems. Especially, the decreased physical capacities cause elderly people to rely on others to perform daily activities such as showering, dressing, and eating. The lack of independence in activities of daily living (ADL) decreases their quality of life and exaggerate financial burden for family healthcare.   According to studies on affected daily activities of older adults, the showering activity needs more frequent assistance than any other ADL. Existing commercial products, such as Tutti Assisted Bath Tub and Sit & Shower, can provide automated bathing assistance for the elderly people. However, the available products are usually time-based passive cleaning that lacks active physical interactions with users, and thus they do not have some basic functionalities during showering such as scrubbing and wiping. Alternatively, robotic arms can provide active support in showering activity. Recent soft robotics technologies ensure safe and comfortable human-robot interactions. With different types of actuation (e.g. pneumatic, cable-driven), soft robotic manipulators can have dexterous motions and adaptable stiffness to achieve desired tasks. The technology consists of a soft robotic arm and machine learning based algorithm. It can assist elderly people during showering activities according to the user’s needs. As an example, the robotic shower can wash body parts that may difficult to reach, like the back or lower part of the legs. In particular, it has unique features that include:  Safe and comfortable human-robot interaction for pouring water and wiping  Air or water actuation  Affordable and cost effective  The applications include but are not limited to:  Assist showering activity for elderly people  Luxury high-tech showers  Re-purposed to assist disabled people or hospitalized patients  Our robot is based on user-centred design. Soft robotics is widely recognized as enabling safe human-robot interactions owing to its inherent compliance, compared to traditional rigid robots. The soft robot is equipped with machine learning based intelligent algorithms to efficiently accomplish desired assistive tasks.  soft robotics, Soft robot, Assistive healthcare, Aged healthcare, aging Personal Care, Wellness & Spa, Healthcare, Medical Devices, Manufacturing, Assembly, Automation & Robotics